Experiment description of studies that identified CD99L2 in exosomes

1 Experiment ID 275 ISEV standards ✔ EM EV Biophysical techniques ✔ TSG101|Alix|RAB5A EV Cytosolic markers ✔ CD9|CD82|CD63|CD81 EV Membrane markers ✔ AIF EV Negative markers ✔ NTA EV Particle analysis Identified molecule protein Identification method Mass spectrometry PubMed ID 25844599     Organism Homo sapiens Experiment description Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Authors Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. Journal name Oncotarget Publication year 2015 Sample Prostate cancer cells Sample name DU145 - Docetaxel sensitive Isolation/purification methods Filtration Ultracentrifugation Sucrose density gradient Flotation density 1.12-1.19 g/mL Molecules identified in the study Protein Methods used in the study Mass spectrometry/Flow cytometry/Western blotting

Protein-protein interactions for CD99L2

Protein Interactor ExoCarta ID Identification method PubMed Species No interactions are found.

Pathways in which CD99L2 is involved

No pathways found